Corneliu E. Giurgea

From WikiMD's Medical Encyclopedia

Romanian psychologist and chemist



Corneliu E. Giurgea (6 January 1923 – 30 December 1995) was a Romanian psychologist and chemist who is best known for his work in the field of neuroscience and for coining the term "nootropic". He is credited with the synthesis of piracetam, the first compound to be classified as a nootropic.

Early Life and Education[edit]

Corneliu Giurgea was born in Romania in 1923. He pursued his higher education in the field of psychology and chemistry, which laid the foundation for his future contributions to neuroscience. Giurgea's academic journey was marked by a keen interest in understanding the biochemical processes underlying cognitive functions.

Career[edit]

Giurgea's career was primarily focused on the study of the brain and cognitive enhancers. He worked extensively in the development of compounds that could enhance memory and learning. His most notable achievement was the synthesis of piracetam in 1964, a drug that he believed could enhance cognitive functions without the usual side effects associated with psychotropic drugs.

Structure of Piracetam

Development of Nootropics[edit]

Giurgea coined the term "nootropic" in 1972 to describe a new class of psychotropic drugs that enhance cognitive function. The term is derived from the Greek words "nous," meaning "mind," and "tropein," meaning "to bend or turn." According to Giurgea, nootropics should enhance learning and memory, protect the brain against physical or chemical injuries, and possess few side effects.

Piracetam[edit]

Piracetam was the first compound to be classified as a nootropic. It was developed by Giurgea while he was working at the Belgian pharmaceutical company UCB (Union Chimique Belge). Piracetam is believed to enhance cognitive functions by modulating neurotransmitter systems, particularly the acetylcholine system, and improving cerebral blood flow.

Legacy[edit]

Corneliu Giurgea's work laid the groundwork for the development of a new class of drugs aimed at enhancing cognitive function. His pioneering research in nootropics has influenced subsequent studies in the field of cognitive enhancement and neuroprotection. Today, nootropics are widely used and researched for their potential benefits in treating cognitive impairments and enhancing mental performance.

Related Pages[edit]

Navigation: Wellness - Encyclopedia - Health topics - Disease Index‏‎ - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes

Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa

W8MD's happy loser(weight)

Tired of being overweight?

Special offer:

Budget GLP-1 weight loss medications

  • Semaglutide starting from $29.99/week and up with insurance for visit of $59.99 and up per week self pay.
  • Tirzepatide starting from $45.00/week and up (dose dependent) or $69.99/week and up self pay

✔ Same-week appointments, evenings & weekends

Learn more:

Advertise on WikiMD


WikiMD Medical Encyclopedia

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.